ALMDP.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 May 2024 @ 05:44):

Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs...

Stats
Today's Volume	3 775.00
Average Volume	9 806.00
Market Cap	6.10M
EPS	€0 ( 2024-04-16 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-1.920
ATR14	€0.0150 (1.22%)

Medesis Pharma S.A. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medesis Pharma S.A. Financials

Annual	2022
Revenue:	€47 297.00
Gross Profit:	€-2.21M (-4 662.24 %)
EPS:	€-0.630

FY	2022
Revenue:	€47 297.00
Gross Profit:	€-2.21M (-4 662.24 %)
EPS:	€-0.630

FY	2021
Revenue:	€95 729.00
Gross Profit:	€79 024.00 (82.55 %)
EPS:	€-0.606

FY	2019
Revenue:	€230 000
Gross Profit:	€224 000 (97.39 %)
EPS:	€-0.457

Financial Reports:

No articles found.

Medesis Pharma S.A.

Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.